英文标题:Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations 中文标题:阿美替尼辅助治疗伴罕见EGFR突变的完全切除的IA2-IIIA期NSCLC 讲者:H. Ye(...
GENETIC overexpressionBackground: Esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in the Asian belt. These cancers show poor prognosis with an overall 5-year survival rate less than 19%. Exploring new molecular therapeutic targets such as ...
EGFR（Epidermal Growth Factor Receptor，表皮生长因子受体）基因突变是非小细胞肺癌（non-small-cell lung cancer, NSCLC）中最常见的激活突变。一代EGFR靶向药物吉非替尼治疗后的耐药机制中，最常见的是获得性的EGFR T790M，这部分患者可以接着使用第三代靶向药物奥希替尼继续治疗；其次是MET扩增（c-Mesenchymal-epit...
EGFR 基因突变EXON 18 OVEREXPRESSION Allele Registry ID:别名: ClinVar ID: 基因突变位点 Ref. Build:GRCh37Ensembl Version:75 Chr.StartStopRef. sVar. Bases 75523799955238735 Transcript ENST00000344576.2 基因序列
[9]Vivaldi C,et al. HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. Oncologist. 2020 Oct;25(10):886-893. [10]Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met an...
Fig. 1: Major advances in the use of EGFR tyrosine-kinase inhibitors to treat patients with non-small-cell lung cancer. - 图片说明 ◉ 非小细胞肺癌(NSCLC)中关键 EGFR 突变的识别时间线,以及 EGFR 酪氨酸激酶抑制剂(TKIs)在早期(I-II 期)、局部晚期(III 期)和转移性阶段(IV 期)EGFR 突变 NSCLC...
AUTOCRINE ACTIVATION G465R G719 K757R V769_770insASV L861Q L861 V774M EGFR 基因突变 OVEREXPRESSION Allele Registry ID:别名: ClinVar ID: 基因突变位点 Ref. Build: GRCh37 Ensembl Version: 75 Chr. Start Stop Ref. s Var. Bases 7 55086794 55279321 Transcript ENST00000275493.2 基因序列移动...
[3] Wu, Yi-Long, et al. "Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial." The Lancet ...
Overexpression of the EGFR ligand TGF-α also transformed Rat-1 and NRK fibroblasts, as assayed by colony The ErbB receptors and their ligands are frequently expressed in human carcinoma The role of ErbB receptors and their ligands in the pathogenesis of human carcinomas is confirmed by a number...
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor respon